← back to search

Gabriel Contreras

University of Miami · US
Area of research
Nephrology · Rheumatology
Research interest
Research interests include Systemic Lupus Erythematosus Research, Renal Diseases and Glomerulopathies, Blood Pressure and Hypertension Studies, and Dialysis and Renal Disease Management.
h-index
48
citations
11,535
works
146
NIH funding
primary concept
Medicine
email

Recent publications

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
The Lancet Rheumatology 2024cited by 27position: middledoi
Blood Pressure and Cardiovascular Disease Mortality Among US Adults: A Sex-Stratified Analysis, 1999–2019
Hypertension 2023cited by 34position: middledoi
Associations Between Albuminuria and Mortality Among US Adults by Demographic and Comorbidity Factors
Journal of the American Heart Association 2023cited by 18position: middledoi
Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease
Kidney International Reports 2023cited by 15position: middledoi
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clinical Journal of the American Society of Nephrology 2022cited by 67position: middledoi
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Kidney International 2021cited by 190position: middledoi
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
New England Journal of Medicine 2020cited by 946position: middledoi
Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
EBioMedicine 2020cited by 56position: middledoi
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome
Kidney International 2020cited by 55position: middledoi
A Multicenter Randomized Clinical Trial of Hemodialysis Access Blood Flow Surveillance Compared to Standard of Care: The Hemodialysis Access Surveillance Evaluation (HASE) Study
Kidney International Reports 2020cited by 38position: middledoi
OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
Annals of the Rheumatic Diseases 2020cited by 15position: middledoi
Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT
Journal of the American Society of Nephrology 2019cited by 54position: middledoi
Lower kidney allograft survival in African–Americans compared to Hispanic–Americans with lupus
Lupus 2017cited by 14position: lastdoi
Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD
American Journal of Kidney Diseases 2016cited by 93position: middledoi
GFR Estimation Using β-Trace Protein and β2-Microglobulin in CKD
American Journal of Kidney Diseases 2015cited by 151position: middledoi
ESKD, Transplantation, and Dialysis in Lupus Nephritis
Seminars in Nephrology 2015cited by 35position: lastdoi
A Meta‐analysis of Randomized Clinical Trials Assessing Hemodialysis Access Thrombosis Based on Access Flow Monitoring: Where Do We Stand?
Seminars in Dialysis 2015cited by 27position: lastdoi
Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial
Journal of the American Society of Hypertension 2015cited by 15position: middledoi
Comparison of Mortality of ESRD Patients with Lupus by Initial Dialysis Modality
Clinical Journal of the American Society of Nephrology 2014cited by 35position: firstdoi
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach
Kidney International 2013cited by 350position: middledoi
Effects of Dietary Phosphate Restriction and Phosphate Binders on FGF23 Levels in CKD
Clinical Journal of the American Society of Nephrology 2013cited by 148position: middledoi
Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease
Current Opinion in Lipidology 2013cited by 66position: lastdoi
Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations
Lupus 2013cited by 23position: middledoi
Kidney allograft survival of African American and Caucasian American recipients with lupus
Lupus 2013cited by 22position: firstdoi
Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation
American Journal of Transplantation 2012cited by 57position: middledoi
Accuracy of a GFR Estimating Equation Over Time in People With a Wide Range of Kidney Function
American Journal of Kidney Diseases 2012cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Tamara Isakova · Northwestern University4 papers (2012–2014)Alessia Fornoni · University of Miami4 papers (2020–2023)David A. Roth · GlaxoSmithKline (United States)4 papers (2020–2022)Brad H. Rovin · University of Hong Kong4 papers (2020–2022)Richard Furie · Northwell Health4 papers (2020–2022)Y K Onno Teng · Kunming University of Science and Technology4 papers (2020–2022)Yelena Drexler · University of Miami3 papers (2020–2023)Xueqing Yu · Weihai Science and Technology Bureau3 papers (2020–2021)David Roth · University of Miami3 papers (2012–2014)Ana Malvar · Hospital Fernández3 papers (2020–2021)Beulah Ji · GlaxoSmithKline (China)3 papers (2020–2021)Oliver Lenz · University of Miami3 papers (2013–2015)Sandra Merscher · University of Miami3 papers (2020–2023)Tali Elfassy · University of Miami3 papers (2023–2023)Arif Asif · New York City Health and Hospitals Corporation3 papers (2013–2020)Yulia Green · GlaxoSmithKline (Germany)3 papers (2020–2022)Ali Nayer · Stat Medical Devices (United States)3 papers (2013–2014)Shamroop Kumar Mallela · University of Miami2 papers (2020–2020)Amit Saxena · NYU Langone Health2 papers (2020–2020)Myles Wolf · Duke University2 papers (2012–2013)